IRIS
FANIN, Renato
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 22.496
EU - Europa 6.312
AS - Asia 3.713
SA - Sud America 670
AF - Africa 60
Continente sconosciuto - Info sul continente non disponibili 18
OC - Oceania 6
Totale 33.275
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 22.328
UA - Ucraina 2.106
SG - Singapore 1.857
CN - Cina 1.081
DE - Germania 981
IT - Italia 707
FI - Finlandia 671
BR - Brasile 607
RU - Federazione Russa 549
SE - Svezia 477
IE - Irlanda 367
TR - Turchia 188
KR - Corea 165
CA - Canada 140
GB - Regno Unito 126
FR - Francia 110
VN - Vietnam 89
HK - Hong Kong 79
IN - India 67
IR - Iran 43
CZ - Repubblica Ceca 33
AT - Austria 31
PL - Polonia 27
BE - Belgio 24
NL - Olanda 23
CO - Colombia 20
ZA - Sudafrica 20
AR - Argentina 18
EU - Europa 18
TG - Togo 18
UZ - Uzbekistan 17
IQ - Iraq 16
JP - Giappone 16
BD - Bangladesh 15
ES - Italia 14
MX - Messico 14
EG - Egitto 12
RO - Romania 11
AE - Emirati Arabi Uniti 9
RS - Serbia 9
EC - Ecuador 8
ID - Indonesia 8
PK - Pakistan 8
CH - Svizzera 7
LV - Lettonia 7
BG - Bulgaria 6
KG - Kirghizistan 6
AU - Australia 5
IL - Israele 5
JO - Giordania 5
KZ - Kazakistan 5
HU - Ungheria 4
LK - Sri Lanka 4
NP - Nepal 4
PE - Perù 4
VE - Venezuela 4
AZ - Azerbaigian 3
CL - Cile 3
DO - Repubblica Dominicana 3
JM - Giamaica 3
LT - Lituania 3
LU - Lussemburgo 3
MA - Marocco 3
NO - Norvegia 3
OM - Oman 3
PY - Paraguay 3
SA - Arabia Saudita 3
TN - Tunisia 3
AL - Albania 2
BN - Brunei Darussalam 2
DZ - Algeria 2
EE - Estonia 2
GR - Grecia 2
HN - Honduras 2
KE - Kenya 2
KH - Cambogia 2
LB - Libano 2
PA - Panama 2
SK - Slovacchia (Repubblica Slovacca) 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
UY - Uruguay 2
BH - Bahrain 1
BO - Bolivia 1
BY - Bielorussia 1
CR - Costa Rica 1
GE - Georgia 1
GL - Groenlandia 1
HR - Croazia 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LI - Liechtenstein 1
MK - Macedonia 1
NZ - Nuova Zelanda 1
PH - Filippine 1
PS - Palestinian Territory 1
PT - Portogallo 1
QA - Qatar 1
TH - Thailandia 1
TJ - Tagikistan 1
Totale 33.275
Salva come PNG Salva come JPEG
Città #
Fairfield 2.992
Woodbridge 2.894
Houston 1.964
Ann Arbor 1.893
Jacksonville 1.415
Ashburn 1.294
Seattle 1.217
Wilmington 1.128
Chandler 1.108
Singapore 1.004
Cambridge 980
Dearborn 890
Beijing 537
Boardman 485
Princeton 382
Dublin 367
Udine 279
San Diego 188
Izmir 169
Seoul 151
Ogden 99
Ottawa 98
Norwalk 86
Dong Ket 84
Hong Kong 79
Des Moines 78
Los Angeles 66
Hefei 62
New York 60
Nanjing 55
Santa Clara 51
Redmond 50
São Paulo 47
Trieste 47
Munich 45
Kunming 41
Dallas 39
Milan 37
Guangzhou 32
Nuremberg 30
Regensburg 29
Simi Valley 29
Turku 29
Frankfurt am Main 27
Helsinki 25
Brussels 24
Phoenix 24
Jinan 23
Nanchang 23
Toronto 23
Warsaw 23
Hangzhou 21
Saint Petersburg 21
Düsseldorf 20
Leawood 20
Grafing 18
Lomé 18
Shenyang 17
Rio de Janeiro 16
Tashkent 16
Vienna 16
Venezia 15
Bogotá 14
Fuzhou 14
Rome 14
Wuhan 14
Andover 13
Augusta 13
Chengdu 13
Falls Church 13
London 13
San Mateo 13
Shanghai 13
Atlanta 12
Montreal 12
Tokyo 12
Washington 12
Zanjan 12
Belo Horizonte 11
Brno 11
Monmouth Junction 11
Prague 11
Ardabil 10
Boston 10
Brasília 10
Lauterbourg 10
Olomouc 10
San Francisco 10
Zhengzhou 10
Chongqing 9
Duino-Aurisina 9
Hyderabad 9
Belgrade 8
Cairo 8
Campinas 8
Curitiba 8
Indiana 8
Hebei 7
Johannesburg 7
Lappeenranta 7
Totale 23.409
Salva come PNG Salva come JPEG
Nome #
Prognostic significance of the detection of tumour cells in peripheral blood stem cell collections in stage II and III breast cancer patients treated with high-dose therapy 245
Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party 207
BAALC overexpression retains its negative prognostic role across all cytogenetic risk groups in acute myeloid leukemia patients 193
The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery 158
Central nervous system fungal infections in allogeneic stem cell transplantation. Outcome of 24 recent cases and literature review 158
Co-administration of proton pump inhibitors and/or of steroids may be a risk factor for low trough concentrations of posaconazole delayed-released tablets in adult patients with hematological malignancies 157
Abdominal abscess and Hafnia alvei septicemia occurring during the aplastic phase after autologous stem-cell transplantation in a patient with diffuse large B-cell lymphoma. 155
Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors 152
Atypical haemolytic-uraemic syndrome at the onset of acute promyelocytic leukaemia. 150
The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation 149
Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia. 149
Low-dose rituximab in adult patients with primary immune thrombocytopenia. 148
Decreased function of Fas and variations of the perforin gene in adult patients with primary immune thrombocytopenia 147
Activity of all-trans-retinoic acid in a case of central nervous system extramedullary relapse of acute promyelocytic leukemia 146
Antifungal prophylaxis with posaconazole in patients with acute myeloid leukemia: dose intensification coupled with avoidance of proton pump inhibitors is beneficial in shortening time to effective concentrations. 145
Multipotent Progenitor Cells Are Present in Human Peripheral Blood. 143
Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the Italian Bone Marrow Donor Registry. 141
Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years 141
Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study 141
Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia 141
Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients. 140
P-glycoprotein (PGP) and lung resistance-related protein (LRP) expression and function in leukaemic blast cells 140
Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia. 139
Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response. 137
B-cell immune reconstitution after allogenic stem cell transplantation and its role in the development of chronic graft-versus-host disease 136
Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study. 135
Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases 135
Fludarabine: an active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma. 134
Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib 134
Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia 134
Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)” 133
Efficacy and safety of rituximab in type II mixed cryoglobulinemia. 132
Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results 132
Granulocyte colony-stimulating factor (G-CSF) allows the delivery of effective doses of CHOP and CVP regimens in non-Hodgkin lymphomas. 132
Management of immune thrombocytopenia in elderly patients 132
Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. 130
ABCG2, Cytogenetics, and Age Predict Relapse after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission 129
Purging of chronic myelogenous leukemia cells by retrovirally expressed anti-bcr-abl ribozymes with specific cellular compartmentalization. 128
“Overexpression of multidrug resistance-associated P-170 glycoprotein in acute non lymphocytic leukemia”. 127
Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi 127
Differences among young adults, adults and elderly chronic myeloid leukemia patients. 126
Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab. 126
Long-Term Follow-Up of a Donor versus No-Donor Comparison in Patients with Multiple Myeloma in First Relapse after Failing Autologous Transplantation 125
Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: A multicenter retrospective study based on donor availability 125
P-glycoprotein, lung resistance-related protein and multidrug resistance-associated protein in de novo adult acute lymphoblastic leukaemia. 124
Quality of life in elderly patients with essential thrombocythaemia. An Italian multicentre study. 124
ABCG2 overexpression in patients with acute myeloid leukemia: Impact on stem cell transplantation outcome 124
Pre-Chemotherapy risk factors for invasive fungal diseases: Prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (seifem 2010-a multicenter study) 124
Risk of sinusoidal obstruction syndrome in allogeneic stem cell transplantation after prior gemtuzumab ozogamicin treatment: A retrospective study from the Acute Leukemia Working Party of the EBMT 124
Efficacy and safety of rituximab in type II mixed cryoglobulinemia 123
Autologous stem cell transplantation in chronic carriers of hepatitis B virus and hepatitis C virus affected by onco-hematologic diseases. 123
A comparison of allografting with autografting for newly diagnosed myeloma 122
Bendamustine in chronic lymphocytic leukemia: Outcome according to different clinical and biological prognostic factors in the everyday clinical practice. 122
A phase II study of α-interferon and oral arabinosyl cytosine (YNK01) in chronic myeloid leukemia 122
Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells. 122
Autologus stem cell transplantation as postremission therapy for acute myeloid leukemia. Risk factors at diagnosis can predict the outcome. 121
Family history of cancer and risk of second malignancies in young cancer patients in Trieste, Italy. 121
Granulocyte-macrophage colony -stimulating factor in acute nonlymphocytic leukemia before and after chemo therapy”. 121
Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia 121
Longitudinal follow-up of WT1 gene expression as monitoring of minimal residual disease in acute myeloid leukemia following allogeneic bone marrow transplant 120
Variability of Voriconazole Trough Levels in Haematological Patients: Influence of Comedications with cytochrome P450(CYP) Inhibitors and/or with CYP Inhibitors plus CYP Inducers. 120
Risk Factors and Outcomes of Infections by Multidrug-Resistant Gram-Negative Bacteria in Patients Undergoing Hematopoietic Stem Cell Transplantation 119
A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study 119
ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia 119
Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patients. 118
Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin. 118
WHO classification and WPSS predict post-transplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) 117
Imatinib mesylate (Glivec) pre-treatment does not have a negative effect on outcome of allogenic hematopoietic stem cell transplantation in Philadelphia-positive leukemias 117
Donor compatibility and performance status affect outcome of allogeneic haematopoietic stem cell transplant in patients with relapsed or refractory acute myeloid leukaemia 117
Best practice recommendations in: (1) Peripheral blood stem cell mobilization and collection and (2) acute and chronic GvHD treatment using extracorporeal photopheresis. A joint effort from SIdEM (Società Italiana di Emaferesi e Manipolazione Cellulare) and GITMO (Gruppo Italiano Trapianto di Midollo Osseo). 116
Long-term efficacy and safety of nilotinib therapy after imatinib failure in eosinophilic myeloproliferative neoplasm and ETV6-ABL rearrangement 116
Multicentre survey to explore current survival of patients with acute myeloid leukaemia who failed induction chemotherapy 116
Multipotent Mesenchymal Stem Cells Can Be Isolated and Grown from Many Tissues (Bone Marrow, Liver and Heart) 116
Clinical outcome of myeloid sarcoma in adult patients and effect of allogeneic stem cell transplantation. Results from a multicenter survey 115
High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission 115
Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO Group 115
Unexpected phenotype of a typical NPM1 mutant 114
Impact of hepatitis C virus infection on clinical features, quality of life and survival of patients with lymphoplasmacytoid lymphoma/immunocytoma 114
EUTOS score predicts long-term outcome but not optimal response to imatinib in patients with chronic myeloid leukaemia. 114
Brain natriuretic peptide level as marker of cardiac function in imatinib--treated chronic myeloid leukemia patients: no evidence of cardiotoxicity of imatinib therapy. 114
Treatment of elderly patients (> or =60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols. 114
Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma. 114
ABCG2 and CD200 define patients at high risk of relapse in ELN favorable subgroup of AML 114
Rituximab for the treatment of type II mixed cryoglobulinemia. 113
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia 113
Wilms' tumor 1 gene expression levels in acute promyelocytic leukemia compared to other acute myeloid leukemia subtypes 113
Response rate and survival after thalidomide-based therapy in 248 patients with myelodysplastic syndromes. 112
The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia-- analysis of 848 patients 112
Nocardiosis with favourable clinical outcome in progressive B-chronic lymphocytic leukaemia 112
Clinical factors predictive of myelofibrotic evolution in patients with polycythemia vera. 112
BCL-2 immunohistochemical evaluation in B-cell chronic lymphocytic leukemia and hairy cell leukemia before treatment with fludarabine and 2-chloro-deoxy-adenosine 112
Nonpermissive HLA-DPB1 disparity is a significant independent risk factor for mortality after unrelated hematopoietic stem cell transplantation 111
CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma 111
The role of MDR-related proteins in the prognosis of adult acute myeloid leukaemia (AML) with normal karyotype 111
Allogeneic hematopoietic cell transplantation for primary refractory acute lymphoblastic leukemia: A report from the Acute Leukemia Working Party of the EBMT 111
Antibody binding capacity for evaluation of MDR-related proteins in acute promyelocytic leukemia: Onset versus relapse expression 111
Acute promyelocytic leucemia: low expression of multidrug resistance phenotype at onset suggest a favourable effect of gentuzumab ozogamicyn (CMA-676 110
Paraneoplastic cerebellar degeneration associated with anti-neuronal anti-Tr antibodies in a patient with Hodgkin's disease 110
Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 years treated with induction regimens including fludarabine: retrospective analysis of 224 cases 110
Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index: a prospective, multicenter GITMO study. 110
Totale 12.857
Salva come PNG Salva come JPEG
Categoria #
all - tutte 128.897
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 128.897
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020602 0 0 0 0 0 0 0 0 0 0 0 602
2020/20214.950 134 598 144 577 207 617 356 600 644 183 596 294
2021/20223.100 117 364 156 225 93 144 185 143 56 507 634 476
2022/20232.817 419 159 31 328 259 829 14 207 384 37 86 64
2023/2024853 122 66 27 27 132 100 17 53 142 65 32 70
2024/20255.074 149 502 381 170 292 309 407 426 665 603 1.093 77
Totale 34.304